Login to Your Account

Regeneron drug puts pain on the wane, topline data show

By Michael Fitzhugh
Staff Writer

Monday, May 2, 2016

All four doses of fasinumab, a nerve growth factor therapy under development at Regeneron Pharmaceuticals Inc., helped 338 patients with moderate-to-severe osteoarthritis pain in their hip or knee.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription